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Background:Informant-based questionnaires may have utility for cognitive impairment or 66 
dementia screening. Reviews describing accuracy of respective questionnaires are available, 67 
but their focus on individual questionnaires precludes comparisons across tools.  We 68 
conducted an overview of systematic reviews to assess comparative accuracy of informant 69 
questionnaires and identify areas where evidence is lacking.   70 
Methods:We searched 6 databases to identify systematic reviews describing diagnostic test 71 
accuracy of informant questionnaires for cognitive impairment or dementia.  We pooled 72 
sensitivity and specificity data for each questionnaire and used network approaches to 73 
compare accuracy estimates across the differing tests.  We used Grading of 74 
Recommendations, Assessment, Development and Evaluation (GRADE) to evaluate overall 75 
certainty of evidence.  Finally, we created an evidence ‘heat-map’, describing availability of 76 
accuracy data for individual tests in differing populations and settings.  77 
Results:We identified 25 reviews, consisting of 93 studies and 13 informant questionnaires.  78 
Pooled analysis (37 studies;11,052 participants) ranked the 8-item interview to Ascertain 79 
Dementia (AD8) highest for sensitivity (90%; 95%CrI=82%-95%; ‘best-test’ probability=36%); 80 
while the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) was most 81 
specific (81%; 95%CrI=66%-90%; ‘best-test’ probability=29%).  GRADE-based evaluation of 82 
evidence suggested certainty was ‘low’ overall. Our heat-map indicated only AD8 and 83 
IQCODE have been extensively evaluated and most studies have been in the secondary care 84 
setting.   85 
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Conclusions:AD8 and IQCODE appear to be valid questionnaires for cognitive impairment or 86 
dementia assessment. Other available informant-based cognitive screening questionnaires 87 
lack evidence to justify their use at present.  Evidence on accuracy of available tools in 88 
primary care settings and with specific populations is required.  89 
 90 
Key words: Cognitive impairment; dementia; informant; screening; systematic review; 91 
overview; informant 92 
  93 
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Background   94 
Various assessment tools are available for screening of cognitive impairment or dementia. 95 
The most commonly used tests directly assess cognition via questions or ‘pencil and paper’ 96 
tasks. (Harrison, Noel-Storr, Demeyere, Reyish, & Quinn, 2016) These direct assessments 97 
provide a ‘snapshot’ of cognitive function that does not capture change in cognition, yet 98 
cognitive deterioration is a fundamental component of dementia diagnosis. In addition, 99 
direct assessments are often compromised, or not possible, in various acute secondary care 100 
settings. (Elliott et al., 2019) There is a need, therefore, to identify measures that can 101 
provide an alternative to traditional ‘direct’ cognitive screening methods.   102 
An attractive approach is to assess cognition using informant-based interview tools.  103 
Through this method, a patient’s close relative or friend (i.e. informant) is used to indirectly 104 
identify temporal change in patients’ cognition and related function. 105 
There are several informant tools available that are used in practice, such as the Informant 106 
Questionnaire on Cognitive Decline in the Elderly (IQCODE), (Jorm and Jacomb, 1989) the 8-107 
item interview to Ascertain Dementia (AD8), (Galvin et al., 2005) and the General 108 
Practitioner Assessment of Cognition (GPCOG). (Brodaty et al., 2002) Current guidelines 109 
recommend use of structured informant interviews for cognitive assessment, but do not 110 
recommend a particular tool in preference to others. (NICE, 2020)  111 
A number of systematic reviews have attempted to establish the diagnostic accuracy of 112 
informant-based tools in order to inform best tool selection. (Quinn et al., 2014; Harrison et 113 
al., 2014; Harrison et al., 2015; Harrison et al., 2016) However, this rapidly growing literature 114 
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may be overwhelming for clinicians and decision-makers, and to date has only considered 115 
available tools in isolation, precluding an answer to the question: which tool is best?   116 
Novel evidence synthesis techniques (Owen RK, Cooper NJ, Quinn TJ, Lees R, & Sutton, 117 
2018) allow for comparative assessment and are well suited to analysis of the accuracy of 118 
the various informant tools.  A synthesis of published systematic reviews, i.e. an overview of 119 
systematic reviews, combined with a comparative summary could help to concisely 120 
summarise the broader evidence-base, improving clinicians’ and policy makers’ ability to 121 
select or recommend tools for cognitive assessment.     122 
Aims and objectives  123 
We performed an overview of systematic reviews to draw together results from systematic 124 
reviews of the diagnostic properties of informant-based cognitive screening tools.  125 
Our primary question was: what is the comparative accuracy of informant-based screening 126 
tools for identifying cognitive impairment or dementia?  127 
Secondary objectives 128 
Where possible, we used this overview of systematic reviews to inform a number of 129 
secondary objectives: 130 
To determine variability in informant tool diagnostic test accuracy across various settings 131 
and cognitive syndromes. 132 
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To evaluate the quality of systematic reviews of diagnostic test accuracy research such that 133 
common methodological issues can be highlighted, and standards improved.  134 
To produce an ‘evidence map’ that reveals gaps in the evidence-base where new primary 135 
research is needed. 136 
 137 
Methods   138 
Design 139 
We used the PRISMA (preferred reporting for systematic review and meta-analysis) checklist 140 
for reporting in this overview of systematic reviews.  (see supplemental materials e-1) 141 
Design, conduct and interpretation of overviews of systematic reviews is evolving; we 142 
followed recent best practice guidance. (Higgins et al., 2019; McKenzie & Brennan, 2017)   143 
All aspects of searching, data extraction and review assessment were performed by two 144 
reviewers independently, with recourse to a third arbitrator where disagreement could not 145 
be resolved.   146 
A detailed description of our methodology can be seen in the previously published protocol. 147 
(Taylor-Rowan, Nafisi, Patel, Burton & Quinn, 2020)  A summary of our methodology is 148 
provided in the sections below.  149 
Inclusion and exclusion criteria 150 
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We included systematic reviews that investigated the diagnostic properties (test accuracy) 151 
of an informant-based cognitive screening tool. We included reviews conducted in any 152 
setting or patient population. We operationalised the settings in which informant tools are 153 
used as: secondary care, primary care, and community.  We made no exclusions on the basis 154 
of methodological quality, use of best practice methods, or approach to data synthesis.   155 
Reviews were excluded if they exclusively reported on the diagnostic test accuracy of 156 
telephone-based assessment, prognostic accuracy, or ‘functional’ informant tools that 157 
measure ability to perform activities of daily living, rather than cognition per se.  We also 158 
excluded non-English language reviews.   159 
Search methods for identification of reviews   160 
We searched EMBASE (OVID); Health and Psychosocial Instruments (OVID); Medline (OVID); 161 
CINAHL (EBSCO); PSYCHinfo (EBSCO) and the PROSPERO registry of review protocols.  All 162 
databases were searched from inception to December 2019.  Search syntax can be seen in 163 
supplementary materials (e-2). 164 
We additionally contacted authors working in the field of dementia test accuracy to identify 165 
other relevant systematic reviews, and studied reference lists of all included reviews in 166 
order to identify additional titles not found by our search. (Greenhalgh & Peacock, 2005) 167 
 168 
Data collection and analysis   169 
Title selection and data extraction   170 
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Titles were screened using Covidence systematic review software, Veritas Health 171 
Innovation, Melbourne, Australia, available at www.covidence.org.  Data was extracted on 172 
to a data collection proforma that was specifically designed by the author team (see 173 
supplementary materials; e-3) 174 
Assessment of methodological and reporting quality of included reviews   175 
Methodological quality of included reviews was evaluated using a modified version of the 176 
AMSTAR-2 (assessment of multiple systematic reviews) measurement tool (Shea et al., 177 
2017) which considered the following key domains: clarity of review objective; description 178 
of study eligibility criteria; extent of searching undertaken; transparency of assessment 179 
process; assessment of publication bias; assessment of heterogeneity. Overall study quality 180 
conclusions were established based on guidance from Shea et al. (2017). However, as this 181 
guidance is based on reviews of healthcare interventions, we modified the critical domains 182 
to include only: adequacy of the literature search (item 4); risk of bias from individual 183 
studies included in the review (item 9); appropriateness of meta-analytical methods (item 184 
11); and consideration of risk of bias when interpreting the results of the review (item 13). 185 
(see supplementary materials; e-4) 186 
AMSTAR-2 assessment was complimented with an evaluation of reporting standards of 187 
included reviews, utilising the PRISMA-DTA (Preferred Reporting Items for a Systematic 188 
Review and Meta-analysis of Diagnostic Test Accuracy Studies) checklist. (McInnes et al., 189 
2018)  190 
Data synthesis   191 
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We extracted data for analyses directly from original papers identified within respective 192 
reviews. We calculated summary estimates for each informant questionnaire using the 193 
bivariate approach (Reitsma, Glas, Scholten, Bossuyt & Zwinderman, 2005). Where suitable 194 
data (defined below) were available, we then conducted comparative analyses, creating a 195 
network where each questionnaire at a particular threshold score is a node and inferences 196 
around relative test performance can be made through indirect comparison and ranking. 197 
We used a bivariate network meta-analysis model accounting for the correlations between 198 
multiple test accuracy measures from the same study. (Owen et al., 2018; O’Sullivan, 2019) 199 
All models were estimated in a Bayesian framework using Markov Chain Monte Carlo 200 
(MCMC) simulation and implemented in the WinBUGS 1.4.3 software. (Lunn, Thomas, Best, 201 
& Spiegelhalter., 2000) Non-informative prior distributions were specified for test and 202 
threshold-specific accuracy parameters. Informant-based screening tools with the highest 203 
sensitivity and specificity were ranked in first place at each MCMC iteration. The estimated 204 
rankings overall were calculated as a summary of the individual ranks at each iteration. The 205 
probability that each screening tool was the best overall was calculated as the proportion of 206 
MCMC iterations that each informant tool ranked in first place. Further details on the 207 
analyses used are available in the original paper describing the method. (Owen et al., 2018) 208 
We only included studies that evaluated informant tool test accuracy against a diagnostic 209 
standard consistent with recognised criteria for diagnosis of dementia or MCI (e.g. ICD-10, 210 
DSM III-V).  We attempted meta-analysis where informant tools were assessed in at least 211 
two studies. Case-control studies were excluded due to the potential to over inflate test 212 
accuracy.   For our primary analysis, we restricted analysis to the cut-points that were most 213 
regularly used and of most clinical relevance (3.3. and 3.6 for IQCODE; 2 & 3 for AD8).  As 214 
10 
 
our primary question was to evaluate the accuracy of tools as measures of cognitive 215 
impairment or dementia (all inclusive), we did not discriminate between forms of cognitive 216 
impairment evaluated in included studies.  However, where single studies provided 217 
sensitivity and specificity data for multiple forms of cognitive screening (e.g. 218 
sensitivity/specificity values for screening of dementia vs no dementia and 219 
sensitivity/specificity values for screening ‘any cognitive impairment’ vs normal cognition), 220 
we selected one reported sensitivity and specificity figure based on the following hierarchy: 221 
‘any cognitive impairment vs normal cognition’> ‘dementia vs no dementia’> ‘Mild Cognitive 222 
Impairment’ (MCI)vs normal cognition’.  223 
We employed GRADE (Grading of Recommendations Assessment, Development, and 224 
Evaluation) (Guyatt et al., 2008) to evaluate overall strength of sensitivity and specificity 225 
evidence for each tool in our meta-analysis, following recommended guidelines on 226 
application of GRADE to diagnostic test accuracy evidence. (Singh, Chang, Matchar & Bass., 227 
2012) 228 
Subgroup analysis 229 
In addition to our primary analysis, we conducted a subgroup analyses designed to provide 230 
specific data on performance of tools when used to screen for cognitive syndromes of 231 
differing severity and when used in particular settings. Specifically, we evaluated 232 
performance of respective informant tools when used to differentiate between people with 233 
and without dementia (dementia vs no dementia) and between people with MCI and 234 
normal cognition (MCI vs normal cognition).  For each analysis, we sub-grouped by setting 235 
(primary care, secondary care and community care), where possible.   236 
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Sensitivity analysis 237 
We conducted a sensitivity analysis restricting to studies that had no high risk of bias 238 
categories and at least 50% low risk of bias categories (based on individual study level data 239 
within the included review). 240 
 241 
Method for generation of evidence map 242 
In addition to our search for relevant reviews, we identified individual (i.e. non-review) 243 
informant-based diagnostic test accuracy studies to generate an ‘evidence heat-map’.   244 
Search strategy for evidence map 245 
We accessed referenced studies in included reviews and supplemented this with a search of 246 
study reference lists and, where provided, review exclusion lists for further available 247 
studies.  248 
Inclusion/exclusion criteria for evidence map 249 
To be included in the evidence heat-map, individual studies could be either cohort or case-250 
control, but were required to be published in a peer-reviewed scientific journal and report 251 
on the diagnostic test accuracy (i.e. sensitivity and specificity) of an informant tool.  We 252 
included non-English language papers in our evidence heat-map, but studies were excluded 253 
if they reported participant numbers <20; were abstracts; were repeat data sets; assessed 254 
prognostic diagnostic test accuracy; described a ‘functional’ informant measure only (e.g. 255 
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Independent activities of daily living scale); or if the informant tool was completed by 256 
patients rather than informants.  257 
Extent of available evidence was depicted via a shading scheme ranging from dark (0-10 258 




Our search identified 4865 titles.  After screening, we found 25 reviews (including 93 263 
studies) that met our inclusion criteria. (see Table 1) Details of the screening process and 264 
reasons for each exclusion can be seen in supplementary materials (e-5). 265 
[insert Table 1] 266 
Summary of reviews’ findings 267 
Thirteen informant-based assessment tools were discussed in included reviews. The 268 
diagnostic test accuracy properties of 11 of these tools were described.  Each reviewed tool 269 
is presented below.    270 
IQCODE  271 
The most comprehensively assessed informant tool was the IQCODE, which was included in 272 
18 reviews and 52 original studies.  Five distinct versions of the IQCODE were described 273 
based on the number of component question items (IQCODE-32, IQCODE-26, IQCODE-16, 274 
IQCODE-17, IQCODE-7); the most commonly used versions were the 26-item and the 16-275 
item adaptation.   276 
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Pooled estimates of IQCODE accuracy for dementia diagnosis ranged from sensitivity 80-277 
91% and specificity 66-85%.  Review evaluations of IQCODE diagnostic test accuracy studies 278 
suggested study quality was generally poor.  In Cochrane reviews, (Quinn et al., 2014; 279 
Harrison et al., 2014; Harrison et al., 2015) just 2/25 IQCODE studies were judged to have no 280 
high risk of bias categories.  Typical issues were around lack of blinding and unnecessary 281 
patient exclusions—particularly removal of those who may benefit most from an informant-282 
based assessment (e.g. patients with comorbidities that make traditional cognitive 283 
assessments challenging).   284 
AD8 285 
The AD8 was assessed in 5 reviews (20 studies).  Pooled sensitivity rates for dementia 286 
diagnosis ranged from 88-97% and pooled specificity rates ranged from 64-81%.  Cochrane 287 
review evaluations (Hendry et al., 2019) determined that 4/10 AD8 studies had no high risk 288 
of bias categories.  Areas of study limitation were around inadequate reporting, 289 
inappropriate exclusions of participants, and high participant drop-out rates due to inability 290 
to complete tests.   291 
GPCOG 292 
The GPCOG was evaluated in 6 reviews, describing 5 distinct studies.   293 
All but two reviews evaluated the diagnostic test accuracy of the GPCOG based on the 294 
evidence of just 1 ‘fair quality’ (Lin, O’Connor, Rossom, Perdu & Eckstrom., 2013) study. A 295 
more recent review (Tsoi, Chan, Hirai, Wong & Kwok., 2015) evaluated 5 GPCOG studies and 296 
reported a pooled sensitivity of 92% and specificity of 87%.  However, risk of bias was 297 
substantial (25% of studies rated high risk of bias in 3 out of 4 domains).  Unlike most other 298 
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informant tools, the GPCOG has a combined patient and informant assessment.  When the 299 
informant component of the GPCOG was used in isolation, it appeared to have poor 300 
specificity (49-66%). (Kansagara & Freeman., 2010)  301 
Other informant-based assessment tools 302 
Ten additional informant tools were described in at least one included review.  A summary 303 
of the diagnostic test accuracy evidence for each can be seen in Table 2.  304 
[insert Table 2] 305 
Network meta-analysis  306 
From each review, we identified a total of 37 suitable studies (11,052 participants) to 307 
evaluate comparative performance of respective tools.  One study (Jorm et al., 1996) 308 
provided direct (within study) comparative data on the IQCODE-26 and IQCODE-16; 2 309 
studies (Jackson, MacLullich, Gladman, Lord & Sheehan, 2016; Razavi et al., 2014) provided 310 
direct comparative data on IQCODE-16 and AD8.  All other studies provided test accuracy 311 
properties of single informant tools in isolation, meaning indirect (between study) 312 
comparisons were predominant in our network meta-analyses.  313 
Primary analysis 314 
Our primary network meta-analysis examined performance of informant tools as measures 315 
of cognitive impairment or dementia (all inclusive).  Only 3 informant tools had sufficient 316 
data for comparative analysis (IQCODE-26; IQCODE-16 & AD8).   317 
Results suggest AD8 at cut-point 2 may have the highest sensitivity (90%; 95% credible 318 
intervals [CrI]=82%-95%; ‘best test’ probability=36%) for detecting cognitive impairment or 319 
dementia, although there was little difference between AD8 at cut point 2, AD8 at cut point 320 
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3 and IQCODE-16 at cut point 3.6 with probability best of 36%, 23%, and 22% respectively.  321 
IQCODE-26 at cut-point 3.6 may have the highest specificity (81%; 95%CrI=66%-90%; ‘best 322 
test’ probability= 29%), though again there was little difference between IQCODE-26 at cut-323 
point 3.6, IQCODE-16 at cut point 3.6, and IQCODE-16 at cut point 3.3 with probability best 324 
of 29%. 26% and 17%, respectively.  We noted that two studies (Jackson, MacLullich, 325 
Gladman, Lord & Sheehan, 2016; de Jonghe, 1997) were conducted in distinct populations 326 
(delirious and depressed, respectively) that could alter diagnostic test accuracy properties.  327 
We therefore conducted an additional sensitivity analysis, removing these 2 studies.  Results 328 
were unchanged. (see supplementary materials; e-6)  329 
Comparative performance for each tool at respective cut-points can be seen in Table 3.   330 
[insert Table 3] 331 
Subgroup analysis 332 
We evaluated the performance of tools when screening for a specific cognitive syndrome in 333 
a particular setting.  Sufficient data for pooling in this subgroup analysis was only available 334 
for respective tools at certain cut-points.  (see Table 4) 335 
Comparative data on tool performance for ‘dementia vs no dementia’ screening suggests 336 
that the AD8 at cut-point 2 may have the highest sensitivity for dementia in both secondary 337 
care (96%; 95%CrI=72-99%; ‘best test’ probability= 76%) and community settings (86%; 338 
95%Crl=64-95%; ‘best test’ probability=48%).  IQCODE-16 at cut point 3.3 had the greatest 339 
specificity for dementia assessment in secondary care (71%; 95%Crl=35-93%; ‘best test’ 340 
probability=73%) while IQCODE-26 at cut-point 3.6 had the highest specificity (93%; 341 
95%CrI=81-98%%; ‘best test’ probability=90%) in the community.   342 
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Comparisons of general tool performance across settings suggest sensitivity of each tool is 343 
consistently higher when used in the secondary care setting than when used in the 344 
community (secondary care sensitivity range: 82-96%; community care sensitivity range: 68-345 
86%), whereas specificity is comparatively reduced (secondary care specificity range: 39-346 
71%; community care specificity range:71-93%).  347 
[insert Table 4] 348 
There were insufficient studies to compare tool performance when used in primary care or 349 
for assessing MCI vs normal cognition. 350 
 351 
Risk of Bias sensitivity analysis 352 
We evaluated reported rates when restricted to studies deemed to be at lower risk of bias.  353 
Seven studies were available in total; however, there was too much heterogeneity to pool 354 
data, hence individual study findings were assessed. (Supplementary materials, e-6) The 355 
general trend of informant tool performance was consistent with our pooled analyses. 356 
Strength of overall evidence 357 
Our GRADE rating of the strength of the IQCODE and AD8 diagnostic test accuracy evidence 358 
was ‘low’ for sensitivity and specificity of both tools, primarily due to the risk of bias present 359 
in included studies and the imprecision apparent in our pooled rates. (see supplementary 360 




Overview of systematic reviews—evaluation of review methodological and reporting 363 
quality 364 
Our AMSTAR-2 evaluations highlighted a number of methodological issues in included 365 
reviews.  Overall review quality was mixed: 8/25 (32%) reviews were ‘critically low’ quality; 366 
6/25 (24%) reviews were rated moderate and 3/25 (12%) were high methodological quality.  367 
All reviews rated moderate or above were conducted from 2010 onwards (see supplemental 368 
materials for AMSTAR-2 evaluation, e-8).  All reviews performed a comprehensive search 369 
and study inclusion criteria was generally adequately explained.  However, a number of 370 
reviews did not perform the systematic search and/or conduct data-extraction in duplicate 371 
via 2 independent investigators (9/25; 36%); errors in data extraction were frequent, and 372 
very few reviews pre-registered a protocol (5/25; 20%).  373 
Meta-analyses were performed in 11/25 (44%) reviews and appropriate statistical methods 374 
were used in each—though it was common for reviews to include case-control studies in 375 
pooled analyses, potentially exaggerating diagnostic test accuracy. (Higgins et al, 2019) 376 
Risk of bias was not adequately investigated in 9/25 (36%) reviews.  Where risk of bias 377 
assessment was conducted, conclusions regarding individual studies were often contrasting.  378 
For instance, Chen et al. (2017) rated all seven included AD8 studies to be ‘high quality’, 379 
identifying no high risk of bias domains in any study; Hendry et al. (2019) rated 4/7 of the 380 
same studies to have at least 1 high risk of bias domain.  No reviews conducted a sensitivity 381 
analysis gauging the impact of high risk of bias studies upon reported pooled results, and 382 
only 1 review (Chen et al., 2017) investigated possible publication bias. 383 
Evaluation of reporting standards via PRISMA-DTA revealed main issues around explicit 384 
statements of objectives (12/25 [48%] studies), describing information sources in adequate 385 
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detail (12/25 [48%] studies) and reporting sufficient details of test accuracy from individual 386 
included studies (11/25 [44%] studies).  387 
 388 
Evidence Map findings 389 
A total of 93 distinct informant tool studies were identified and diagnostic test accuracy 390 
properties were described across a range of settings and populations. (Figure 1) Our findings 391 
suggests that IQCODE and AD8 have a greater evidence-base than other available tools, but 392 
there are a lack of diagnostic test accuracy evaluations in primary care and specialised 393 
populations (e.g. stroke).  References of included papers, along with risk of bias judgements 394 
for each included study can be seen in supplementary materials (e-9). 395 




Comparative evidence for available tools 400 
At least 13 informant tools for cognitive assessment are available, though there is a lack of 401 
evidence to justify use of all but two of these tools: the IQCODE and the AD8.  The reviewed 402 
literature suggests that both tools have reasonable diagnostic test accuracy for assessment 403 
of cognitive impairment or dementia, comparable with other popular cognitive screening 404 
tools such as the Mini Mental State Examination and Montreal Cognitive Assessment. (Tsoi, 405 
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et al., 2015) Our network meta-analysis indicates the AD8 may be the more sensitive of the 406 
two tools, and the IQCODE the more specific; however, the credible intervals (CrI) were 407 
overlapping and estimates of ‘best test’ probability were close for both sensitivity and 408 
specificity, implying little performance difference between respective tools.  The overall 409 
strength of the available evidence was also low according to our GRADE evaluation, 410 
tempering conclusions.   411 
Our findings highlight that the general performance of each tool is variable and typically 412 
lower than originally suggested by the developers. (Jorm & Jacomb, 1989; Galvin et al., 413 
2005) Moreover, while both tools appear capable of screening for dementia, test 414 
performance may vary by setting.  When used in specialised secondary care settings, where 415 
specificity may be the preferred property, at traditional clinical thresholds neither tool 416 
appears well-suited to differentiating patients with dementia from those with mild or age-417 
related cognitive changes. Though the IQCODE-16 demonstrated a reasonable specificity of 418 
73% in secondary care at cut point 3.3, this value was inconsistent with the suggested 419 
performance (57%) of the longer IQCODE-26 at a cut point (3.6) that prioritises specificity; 420 
thus, this may be an example of study bias exaggerating tool performance.  Specificity may 421 
be comparatively higher in community settings. However, in this setting, sensitivity may be 422 
the preferred property. 423 
We therefore suggest that neither informant tool is well suited for use as a solitary cognitive 424 
screening tool.  However, these tools can still be useful as solitary assessments in instances 425 
where patients are unable or unwilling to complete a more direct test; thus, where clinicians 426 
seek to employ an informant tool, selection of the IQCODE or AD8 should be guided by 427 
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desire for sensitivity or specificity.  The AD8 at cut point 2 will likely provide the greatest 428 
sensitivity, while the IQCODE-26 at cut point 3.6 will provide the greatest specificity.   429 
It is important to emphasise that our analyses were designed to assess test accuracy only.   430 
Other properties are also important for consideration when selecting an appropriate tool for 431 
cognitive screening.  Feasibility, inter-rater reliability, responsiveness to change, and 432 
suitability for use in specialist populations are all important test characteristics that may 433 
influence the selection of one test over another in clinical practice.  While it is beyond the 434 
scope of this review to discuss each respective tool in these terms, we encourage further 435 
work on this topic to supplement the test accuracy finding we present here.     436 
 437 
The state of diagnostic test accuracy literature  438 
Previous overviews of systematic reviews have highlighted significant issues with regards to 439 
review methodological quality. (Arevalo-Rodriguez et al., 2014) We similarly found prevalent 440 
methodological issues, but also some promising signs. 441 
In contrast to previous diagnostic test accuracy overviews of systematic reviews, the 442 
majority of our included reviews conducted formal risk of bias assessments and the higher 443 
quality reviews were all conducted within the previous decade, suggesting increasing 444 
standards. 445 
However, that risk of bias assessments were inconsistent across reviews indicates a poor 446 
understanding of the ways in which a diagnostic test accuracy study design can introduce 447 
bias.  Existing risk of bias assessment tools typically require investigators to tailor presented 448 
questions to the topic of interest.  The robustness of this modification process is heavily 449 
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impacted by the amount of experience investigators have in the topic area; thus, 450 
subjectivity influences the process of assessing risk of bias even when formal rating tools are 451 
operationalised. Furthermore, study bias is generally under-considered when results are 452 
discussed: conclusions and recommendations are frequently made in reviews without full 453 
exploration of the potential impact biased studies may have had on pooled results.  454 
Clinicians should be mindful of these limitations when consuming the evidence provided in a 455 
review. 456 
 457 
Gaps in the evidence-base 458 
Our evidence map highlights the main areas in which informant tool test accuracy studies 459 
are a priority.  Primary care has comparatively little evidence to other healthcare settings 460 
despite being arguably the most important location for cognitive screening or triage. (Quinn 461 
et al., 2014) Similarly, informant tool diagnostic test accuracy evaluations are lacking in 462 
specialised populations that typically struggle with more traditional cognitive tests (e.g. 463 
stroke populations). We would therefore encourage further work to determine the accuracy 464 
of available informant tools in these populations.  465 
 466 
Future directions  467 
While our data suggest that informant tools may not generally be suitable as solitary 468 
screening tools, they may have utility when combined with direct screening tests. Most 469 
available evidence suggests that direct and informant tools perform better when used 470 
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together. (e.g. Tew, Ng, Cheong, & Yap, 2015; Srikanth et al., 2006; Narasimhalu, Lee, 471 
Auchus, & Chen, 2008) Thus, informant tools may make ideal supplements to the standard 472 
cognitive assessment, yet no reviews exist on this topic.  473 
This type of evaluation is very much needed if we are to confirm the value of a dual (i.e. 474 
direct and informant) approach to assessment.   It is important to note that available tests 475 
(both direct and informant) typically cover varying cognitive domains; (Cullen et al., 2007) 476 
hence, the best combinations of tests may change dependent upon the types of cognitive 477 
problems that are present in a given population.    478 
 479 
Strengths and limitations 480 
We have conducted a comprehensive overview of systematic reviews that brings together 481 
the findings of 25 distinct reviews, depicts an extensive evidence map, and employs new 482 
statistical techniques that allow formal statistical comparisons, ranking, and ‘best test’ 483 
probability estimates between informant tools—addressing a major limitation of this 484 
literature.   485 
However, our overview of systematic reviews has some limitations.  Firstly, the credible 486 
intervals in our network meta-analysis are wide for our specificity estimates and most 487 
included studies are at risk of bias; hence, resultant rankings should not be viewed as 488 
definitive and uncertainty in these estimates should be considered.   489 
Secondly, our comparisons between tools are overwhelmingly based on indirect 490 
comparisons, reliant upon statistical control for random variations in populations—although 491 
our findings are strengthened by a consistency with those studies that directly compared 492 
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the IQCODE and AD8 within the same participant pool. (Jackson, et al., 2016; Razavi et al., 493 
2014). 494 
Thirdly, due to limited study numbers, we were unable to conduct some of our pre-specified 495 
analyses, such as evaluations of tool performance in primary care settings.   496 
Lastly, our evidence map is restricted to studies referenced in published systematic reviews; 497 
thus, there are some recently published studies and informant tools which have not been 498 
reviewed, such as the recently developed Quick Dementia Rating System (Galvin, 2015), that 499 
do not feature. 500 
 501 
Conclusion 502 
Our findings suggest that only the IQCODE and AD8 have had their diagnostic test accuracy 503 
properties widely evaluated.  Based on available data, the AD8 at cut point 2 may be the 504 
most sensitive available tool for detecting cognitive impairment or dementia, while the 505 
IQCODE-26 at cut point 3.6 is the most specific.  However, there is little evidence to suggest 506 
an important difference in tool performance overall, and neither tool performs well enough 507 
to be used alone for dementia assessment. Further evaluations of test accuracy in primary 508 
care and specialised populations are a priority.    509 
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